NeOnc Reports Positive Phase II Results for Intranasal Glioma Therapy

NeOnc Reports Positive Phase II Results for Intranasal Glioma Therapy

NeOnc Technologies’ candidate intranasal therapy, NEO100, achieved positive preliminary results in a Phase II trial in patients with recurrent or progressive late stage glioma brain cancer. Glioma is the most common type of malignant brain tumor in adults, making up around 80% of all cancerous brain tumors. Roughly six out of every 100,000 people in the U.S. are diagnosed with a glioma each year, with the most aggressive form of the brain cancer…

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months